Strong Synergy with WuXi Chemistry and WuXi Biologics
Client Number Overlap between
IND Number Overlap between
WuXi Chemistry and WuXi Testing
WuXi Biologics and WuXi Testing
50%
1500+
200
66
600+
WuXi
Chemistry
Client No.
WuXi
WuXi
Testing
Biologics
IND No.
WuXi
Testing
WuXi Testing: Enable Faster Value Creation for Customers
PCC
IND
POC
NDA
Approval
Preclinical
Early Clinical
Late Clinical
Regulatory
Enable faster project progression
and value creation
from pre-clinical to POC and NDA
PCC
IND
POC
NDA
Approval
Preclinical
Early Clinical
Late Clinical
Regulatory
CRO
Preclinical
SMO
WuXi Testing: Leadership Team
Xu Hui
Jin Yi
Bill Harrison
Shen Liang
Shi Jing
VP, Head of Operation &
VP, Head of PM & RA
VP, Head of Toxicology
VP, Head of DMPK
VP, Head of Bioanalytical
Domestic BD
Chief Scientific Toxicologist
Service
Steve Yang
Co-CEO
Head of WuXi Testing
Ed Amat
LAN LI
Johnathan Lee
Reako Ren
Michael Hui
Mike McGrew
VP, Head of Int'l BD
VP, Head of CL
VP, Head of WuXi Clinical
VP, Head of SMO
VP, Head of QA
VP, Head of Medical Device
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
WuXi AppTec Co. Ltd. published this content on 23 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 August 2021 20:30:09 UTC.
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows:
- laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.;
- CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.;
- clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.;
- other (0.1%).
Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
WUXI APPTEC CO., LTD. 
